EMA review of SCENESSE extended to mid-2014
Filed with ASX ·
6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- JAMA Dermatology publishes SCENESSE vitiligo study results
- EMA Oral Explanation Update
- Clinuvel enters a joint venture with Biotech Lab Singapore
- Clinuvel accredits first European EPP expert centres
- Clinuvel Placement
Later from Clinuvel Pharmaceuticals
- Clinuvel clears EMA manufacturing audit
- Five month study follow up - SCENESSE in vitiligo (CUV102)
- Observations from Clinuvels US vitiligo study published
- SCENESSE successful in Phase IIa vitiligo study
- Appendix 4D - Half Yearly Report
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals